New Whitepaper: Origination in the Age of AI–How signal-driven infrastructure is replacing broker-dependent deal flow.Read now↗

Transaction Intelligence
Transactions
Closed & announced M&A across every sector and state.
Sectors
Browse transactions by industry vertical.
States
Browse transactions by U.S. state.
Buyers
Browse transactions by acquiring company.
On-marketComing soon
Businesses actively listed for sale.
PE Firms M&A Firms Commercial Lenders Investment Banks
Deal Origination
End-to-end outreach infrastructure that sources proprietary deal flow.
Data & Research
TAM mapping, data enrichment, custom scraping, and automated research.
AI Implementation
How Tentt deploys AI across your deal origination stack.
Resources
Playbooks
Channel-specific outreach playbooks for deal origination.
All research
Comparison posts, methodology, and analysis from the Tentt team.
Reports
Monthly market reports on M&A and private equity activity.
Tools
Free calculators for M&A, lending, and deal analysis.
Whitepaper↗
Origination in the Age of AI.
About
Book an intro call

Biogen — Acquisitions & M&A Deals

2 deals

Tracking 2 M&A deals by Biogen.

T - Apellis Pharmaceuticals, Inc. (0001492422) (Subject) — SEC SC TO Filing

HealthcareMassachusettsMerger

Biogen→Apellis Pharmaceuticals

Apr 14, 2026

Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets

HealthcareMassachusettsMerger

Biogen→Apellis Pharmaceuticals

Apr 1, 2026